



UNIVERSITY OF  
GLOUCESTERSHIRE

This is a peer-reviewed, post-print (final draft post-refereeing) version of the following published document, © 2019 American Medical Association (AMA) and is licensed under All Rights Reserved license:

**van Wijngaarden, Peter, Keel, Stuart and Scanlon, Peter H  
ORCID: 0000-0001-8513-710X (2019) The Case for Extended  
Screening Intervals for People With Diabetes and No or  
Minimal Retinopathy at Baseline. JAMA Ophthalmology, 137  
(4). pp. 449-459. doi:10.1001/jamaophthalmol.2018.6901**

Official URL: <http://dx.doi.org/10.1001/jamaophthalmol.2018.6901>

DOI: <http://dx.doi.org/10.1001/jamaophthalmol.2018.6901>

EPrint URI: <https://eprints.glos.ac.uk/id/eprint/6501>

#### **Disclaimer**

The University of Gloucestershire has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material.

The University of Gloucestershire makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.

The University of Gloucestershire makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights.

The University of Gloucestershire accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement.

PLEASE SCROLL DOWN FOR TEXT.

# The Case for Extended Screening Intervals for People with Diabetes and No or Minimal Retinopathy at Baseline

Peter van Wijngaarden\*, PhD<sup>1,2</sup>; Stuart Keel, PhD<sup>1,2</sup>; Peter H. Scanlon, FRCOphth<sup>3,4</sup>

*JAMA Ophthalmology*. 2019. doi:10.1001/jamaophthalmol.2018.6901

The article by Modjtahedi et al<sup>1</sup> in this issue of *JAMA Ophthalmology* is noteworthy because it adds to a growing body of evidence that suggests that extending screening intervals to 2 years for those with no or minimal diabetic retinopathy (DR) at baseline may be safe and appropriate. There is an increasing need for screening intervals to be informed by evidence and tailored to risk, given the aging population and the growing burden of diabetes.

While this study is an important contribution to the field, in isolation, it does not provide sufficient evidence to support the case for biennial screening for the following reasons: (1) it is a retrospective study that captures intervention outcomes alone; (2) it is not clear whether patients seek treatment outside of the health network, in which case intervention outcomes may be underestimated; (3) because 2-year retinopathy severity data are not provided, it is unclear what proportion of people have retinopathy nearing the threshold for therapy; (4) 14.8% of participants were lost to follow-up, and because nonattendance is a risk factor for the complications of diabetes, it is possible that the rates of intervention reported in this study are underestimates of the true burden of sight-threatening disease; (5) the extent to which the study findings can be generalized to other populations is unclear because baseline characteristics of the study participants are not described in detail (key clinical variables, including duration of diabetes, hemoglobin A<sub>1c</sub>, blood pressure levels, and comorbid complications of diabetes, are not provided); and (6) minimal retinopathy is not clearly defined. Other research has suggested that among those with minimal retinopathy (Early Treatment Diabetic Retinopathy Study, level 20), the risk of progression varies significantly according to the number of microaneurysms present.<sup>2</sup> Studies also indicate that the risk of progression to referable DR is significantly higher for those with mild and moderate nonproliferative DR (Early Treatment Diabetic Retinopathy Study, levels 20-35) in both eyes at baseline than in those with mild and moderate nonproliferative DR in 1 eye only.<sup>3,4</sup>

Other studies have explored the cost-benefit association between DR screening intervals and outcomes. Vijan et al<sup>5</sup> suggested in 2000 that annual screening for all patients with type 2 diabetes without previously detected retinopathy was not cost-effective, and tailoring recommendations according to patient age and glycemic control may be preferable. In 2015, Scanlon et al<sup>6</sup> examined the cost-effectiveness of personalized screening intervals, incorporating previous screening outcomes and commonly available baseline clinical data (eg, hemoglobin A<sub>1c</sub>, cholesterol, and blood pressure). Extending screening intervals to every 5 years in the lowest-risk groups (ie, those with no DR in either eye at 2 annual screening episodes) and every 2 years for higher-risk groups (ie, those with mild nonproliferative DR in both eyes) was found to be cost-effective. It is important to note that in this population, the blood pressure and glycemic control was relatively good, and thus, these recommendations may not be appropriate for other populations where risk factor control is less optimal. A trial to validate the introduction of personalized screening intervals is underway in Liverpool, England.<sup>7</sup>

Personalization of screening intervals is likely to be further advanced with the widespread adoption of digital health records and data linkage across health domains. Artificial intelligence–assisted image analysis offers the potential of more accurate progression monitoring and prediction, which may eventually allow for more precisely tailored screening intervals. In the interim, further studies are warranted to understand the suitability of extended intervals in practice. As alluded to by Modjtahedi et al,<sup>1</sup> there is likely to be a tipping point at which compliance with screening falls off as screening

intervals extend because longer intervals may minimize perceived risk and thus patient engagement. The broader health care context is important in this regard: if a DR screening program is embedded in the health system, longer intervals are less likely to result in loss of participation. Experience in health systems where screening is ad hoc, such as in Australia, suggests that compliance with biennial screening is suboptimal.<sup>8</sup>

**Conflict of Interest Disclosures:** None reported.

\*Corresponding author [peter.v@unimelb.edu.au](mailto:peter.v@unimelb.edu.au)

## References

1. Modjtahedi BS, Theophanous C, Chiu S, Luong TQ, Nguyen N, Fong DS. Two-year incidence of retinal intervention in patients with minimal or no diabetic retinopathy on telemedicine screening [published online February 7, 2019]. *JAMA Ophthalmol*. doi:[10.1001/jamaophthalmol.2018.6912](https://doi.org/10.1001/jamaophthalmol.2018.6912). ArticleGoogle Scholar
2. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR; UK Prospective Diabetes Study Group. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). *Diabetologia*. 1999;42(9):1107-1112. doi:[10.1007/s001250051278](https://doi.org/10.1007/s001250051278)PubMedGoogle ScholarCrossref
3. Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. *Acta Ophthalmol*. 2013;91(5):e335-e339. doi:[10.1111/aos.12074](https://doi.org/10.1111/aos.12074)PubMedGoogle ScholarCrossref
4. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight-threatening diabetic retinopathy. *Diabetes Care*. 2013;36(3):580-585. doi:[10.2337/dc12-0625](https://doi.org/10.2337/dc12-0625)PubMedGoogle ScholarCrossref
5. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. *JAMA*. 2000;283(7):889-896. doi:[10.1001/jama.283.7.889](https://doi.org/10.1001/jama.283.7.889)ArticlePubMedGoogle ScholarCrossref
6. Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. *Health Technol Assess*. 2015;19(74):1-116. doi:[10.3310/hta19740](https://doi.org/10.3310/hta19740)PubMedGoogle ScholarCrossref
7. Individualized Screening for Diabetic Retinopathy (ISDR) Project. <http://www.isdrproject.co.uk/index.html>. Accessed October 12, 2018.
8. Tapp RJ, Zimmet PZ, Harper CA, et al; Australian Diabetes Obesity and Lifestyle Study Group. Diabetes care in an Australian population: frequency of screening examinations for eye and foot complications of diabetes. *Diabetes Care*. 2004;27(3):688-693. doi:[10.2337/diacare.27.3.688](https://doi.org/10.2337/diacare.27.3.688)PubMedGoogle ScholarCrossref

**Keywords:** Diabetic retinopathy; Ophthalmology; Diabetes; Retinal disorders